The Combination Effect of Citicoline and Omega-3

This study is a randomized, double-blind, placebo-controlled trial. The investigators
hypothesize that supplementation of Citicoline plus Omega-3 will improve attention in healthy
adults age 55 years and older, compared to placebo. The study is designed as 3-arm, parallel
group study comparing placebo, Omega-3 only, and Citicoline plus Omega-3.

Inclusion Criteria:

- Age 55 years or older

- If female, must be post-menopausal

- Non-demented

- Not depressed

- General health status that will not interfere with the participant's ability to
complete the study

- No history of neurological disorder

- Screening laboratory values within normal limits or, if abnormal, deemed clinically
insignificant by the investigator

- Sufficient English language skills to complete all testing

Exclusion Criteria:

- Alzheimer's, Dementia or other neurological disease

- Fish intake of 6 ounce serving once a week 3 months prior to enrollment; Omega-3
supplement intake (e.g. fish oil capsules, cod liver oil, or flaxseed oil) less than 3
months prior to enrollment.

- Citicoline supplementation 3 months prior to enrollment

- Prescriptions medications:

1. Anticoagulation therapy: Vitamin K antagonist: warfarin (Coumadin, jantoven),
Factor Xa inhibitors: rivaroxaban (xarelto), fondaparinux (arixtra), dibigatran
(pradaxa), apixaban (eliquis); Low molecular weight heparins: dalteparin
(fragmin), enoxaparin (lovenox)

2. Dementia medications (e.g. anticholinesterase inhibitors, memantine)

3. Diagnosis of Adult Attention Deficit Disorder (ADD) or Attention Deficit
Hyperactivity Disorder (ADHD) and/or taking stimulants (e.g. dextroamphetamine
sulfate, methylphenidate HCL, dextroamphetamine Sulf-Saccharate)

- Body Mass Index > 30

- Enrollment in another treatment study